Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program
Jovanka Gencel‐Augusto(University of California, San Francisco), Guillermina Lozano(The University of Texas MD Anderson Cancer Center), Encarnacion Perez(Genesis Laboratories), Iqbal Mahmud(The University of Texas MD Anderson Cancer Center), Elizabeth M. Whitley(Houston Community College System), Vinod Pant(The University of Texas MD Anderson Cancer Center), Marta L. Fiorotto(Children's Nutrition Research Center at Baylor College of Medicine), Shunbin Xiong(The University of Texas MD Anderson Cancer Center), Philip L. Lorenzi(City Of Hope National Medical Center), Nicholas E. Navin(The University of Texas MD Anderson Cancer Center), Xiaoping Su(Guangxi Medical University), Vrutant Shah(Houston Methodist), Jerome Lin(The University of Texas MD Anderson Cancer Center), Abhinav K. Jain(The University of Texas MD Anderson Cancer Center), Yuan Qi(The University of Texas MD Anderson Cancer Center), Ellen R. Richie(The University of Texas MD Anderson Cancer Center)
Cited by 23
Related Papers
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
|Nature Communications|2020|383
Mdm2-mediated ubiquitylation: p53 and beyond
|Cell Death and Differentiation|2009|351